Previous 10 | Next 10 |
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors - IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major s...
IDEAYA Biosciences (IDYA) announced dose expansion of the ongoing Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma ("MUM").The company expects to enroll ~40 patients for the IDE196 and binimetinib combination arm in the trial conducte...
IDEAYA Biosciences (IDYA): Q4 GAAP EPS of -$0.18 beats by $0.04.Revenue of $10.6M beats by $2.68M.Shares -0.34% PM.Press Release For further details see: IDEAYA Biosciences EPS beats by $0.04, beats on revenue
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity - Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM ...
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion - Planning to present data at AACR in Ap...
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196 PR Newswire SOUTH SAN FRANCISCO, Calif. , March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synth...
IDEAYA to Participate in Upcoming March 2021 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to ...
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day ‒ IDEAYA's inaugural Synthetic Lethality Investor Day is planned for April 20, 2021 with scientific presentations from IDEAYA and GSK scientific leaders, and several Key Opinion Leaders ‒ T...
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors - Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the developme...
Ideaya Biosciences (IDYA) announces the effectiveness of Investigational New Drug ((IND)) application for a Phase 1 clinical trial to evaluate IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor.IDE397 is being developed for cancer patients harboring methylthioadenosine phospho...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...